Suppression of inflammation by a synthetic histone mimic
Edwige Nicodeme,
Kate L. Jeffrey,
Uwe Schaefer,
Soren Beinke,
Scott Dewell,
Chun-wa Chung,
Rohit Chandwani,
Ivan Marazzi,
Paul Wilson,
Hervé Coste,
Julia White,
Jorge Kirilovsky,
Charles M. Rice,
Jose M. Lora,
Rab K. Prinjha,
Kevin Lee (kevin.2.lee@gsk.com) and
Alexander Tarakhovsky (tarakho@rockefeller.edu)
Additional contact information
Edwige Nicodeme: Centre de Recherche GSK
Kate L. Jeffrey: Laboratory of Lymphocyte Signaling, The Rockefeller University
Uwe Schaefer: Laboratory of Lymphocyte Signaling, The Rockefeller University
Soren Beinke: Epinova DPU, Immuno-Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline, Medicines Research Centre
Scott Dewell: Genomics Resource Center, The Rockefeller University
Chun-wa Chung: GlaxoSmithKline R&D, Medicines Research Centre
Rohit Chandwani: Laboratory of Lymphocyte Signaling, The Rockefeller University
Ivan Marazzi: Laboratory of Lymphocyte Signaling, The Rockefeller University
Hervé Coste: Centre de Recherche GSK
Julia White: GlaxoSmithKline R&D, Medicines Research Centre
Jorge Kirilovsky: Centre de Recherche GSK
Charles M. Rice: Laboratory of Virology and Infectious Disease, The Rockefeller University
Jose M. Lora: Epinova DPU, Immuno-Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline, Medicines Research Centre
Rab K. Prinjha: Epinova DPU, Immuno-Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline, Medicines Research Centre
Kevin Lee: Epinova DPU, Immuno-Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline, Medicines Research Centre
Alexander Tarakhovsky: Laboratory of Lymphocyte Signaling, The Rockefeller University
Nature, 2010, vol. 468, issue 7327, 1119-1123
Abstract:
Histone mimics target BET bromodomains Small molecules that perturb chromatin proteins are an emerging focus of current biomedical research. Two groups reporting in this issue have targeted bromodomain-containing BET proteins that bind acetylated lysine residues during gene activation, arriving at cell-permeable small molecule compounds with similar structures based on fused triazole-diazepine rings. James Bradner and colleagues report the development of a compound named JQ1. The BET protein BRD4, with two bromodomains, is implicated in human squamous cell carcinoma. JQ1 inhibits the growth of BRD4-dependent tumours in mouse models. Alexander Tarakhovsky and colleagues' inhibitor, I-BET, is shown to interfere with the binding of certain BET family members to acetylated histones. It inhibits activation of pro-inflammatory genes in macrophages and has immunomodulatory activity in a mouse model of inflammatory disease.
Date: 2010
References: Add references at CitEc
Citations:
Downloads: (external link)
https://www.nature.com/articles/nature09589 Abstract (text/html)
Access to the full text of the articles in this series is restricted.
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:468:y:2010:i:7327:d:10.1038_nature09589
Ordering information: This journal article can be ordered from
https://www.nature.com/
DOI: 10.1038/nature09589
Access Statistics for this article
Nature is currently edited by Magdalena Skipper
More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla (sonal.shukla@springer.com) and Springer Nature Abstracting and Indexing (indexing@springernature.com).